 | • レポートコード：MRC2303I0146 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、121ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の医療用医薬品市場規模が、予測期間中（2022年〜2027年）に年平均10.5%で成長すると予測しています。本レポートは、医療用医薬品の世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、薬剤クラス別（脂質調整剤、ACEインヒビター、呼吸器官用薬剤、麻薬性鎮痛剤、その他）分析、用途別（病院＆診療所、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来の動向などを以下の構成でまとめています。また、Amgen Inc、AbbVie Inc、Johnson & Johnson、Eli Lilly and Company、Merck & Co., Inc、GlaxoSmithKline plc、Sanofi、Novartis AG、Abbott Laboratories、Otsuka Holdings、F. Hoffmann-La Roche Ltd、Teva Pharmaceutical Industries Ltd.、Pfizer Inc、Takeda Pharmaceutical Companyなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の医療用医薬品市場規模：薬剤クラス別 - 脂質調整剤の市場規模 - ACEインヒビターの市場規模 - 呼吸器官用薬剤の市場規模 - 麻薬性鎮痛剤の市場規模 - その他薬剤クラスの市場規模 ・世界の医療用医薬品市場規模：用途別 - 病院＆診療所における市場規模 - その他用途における市場規模 ・世界の医療用医薬品市場規模：地域別 - 北米の医療用医薬品市場規模 アメリカの医療用医薬品市場規模 カナダの医療用医薬品市場規模 メキシコの医療用医薬品市場規模 … - ヨーロッパの医療用医薬品市場規模 ドイツの医療用医薬品市場規模 イギリスの医療用医薬品市場規模 フランスの医療用医薬品市場規模 … - アジア太平洋の医療用医薬品市場規模 中国の医療用医薬品市場規模 日本の医療用医薬品市場規模 インドの医療用医薬品市場規模 … - 中東/南米の医療用医薬品市場規模 南アフリカの医療用医薬品市場規模 ブラジルの医療用医薬品市場規模 アルゼンチンの医療用医薬品市場規模 … - その他地域の医療用医薬品市場規模 ・競争状況 ・市場機会・将来の動向 |
The Ethical Pharmaceuticals Market is expected to register a CAGR of 10.5% during the forecast period (2022-2027).
Covid-19 has significantly impacted the ethical pharmaceuticals market due to the rising consumption of drugs related to the respiratory system. For instance, in the Journal of American Pharmacist Association, titled ‘The global impact of COVID-19 on drug purchases: A cross-sectional time-series analysis’ in December 2021, Before COVID-19, the monthly number of standardized pharmaceutical units per 100 people ranged from 3990 to 4760. Compared to 2019, the number of units of pharmaceuticals purchased increased by 15% to 5309.3 per 100 people in March 2020. Furthermore, according to the same source, in the early months of the COVID-19 pandemic, there was evidence of global medicine stockpiling, particularly among developed countries.
The major factors driving the market growth include the rise in the burden of chronic diseases such as diabetes, cancers, and hypertension, the rise in the geriatric population, the rise in product launches for ethical drugs, increase in research and development collaborations to develop novel ethical pharmaceuticals, among others.
The rise in chronic disease is among the major factors driving the market growth. For instance, according to the International Diabetic Federation 2021, diabetes affects around 537 million persons aged 20 to 79. By 2030, the overall number of diabetics is expected to reach 643 million, and by 2045, it will reach 783 million. Furthermore, according to Globocan 2020, there were 19,292,789 new cancer cases seen in 2020 across the globe, and 9,958,133 deaths were reported globally in 2020. Such a huge burden of chronic diseases will lead to increased adoption of ethical medication, driving the market growth significantly.
Furthermore, the rise in collaborations to develop novel drugs has further driven the market growth due to the development and entry of novel drugs into the market. For instance, in March 2020, Curadev Pvt. Ltd. and Bayer entered research cooperation and license agreement for Curadev’s Stimulator of Interferon Genes (STING) antagonist program. The collaboration aims to find new therapeutic candidates for the treatment of lung, cardiovascular, and other inflammatory illnesses.
However, the patent expiry of current ethical pharmaceuticals and the lengthy approval process for these drugs are expected to hinder the market growth.
Ethical Pharmaceuticals Market Trends
Hospitals and Clinics Segment Is Expected To Hold A Major Share In The Market Over The Forecast Period.
The Hospital and Clinics segment is expected to hold a major share in the ethical pharmaceuticals market and continue to do the same over the forecast period.
Due to an increase in hospital admissions due to huge population segments contracting the virus, the tendency to acquire medications prescribed by healthcare providers has increased dramatically. This boosted the broader ethical drug business by increasing product demand.
The rise in hospital admissions is expected to drive market growth. Furthermore, Covid-19 has further impacted the market growth due to the rise in hospital admissions during the pandemic. For Instance, in January 2022, according to the American Academy of Pediatrics and the Children’s Hospital Association, weekly COVID-19 cases in children surpassed 300,000 for the first time since the pandemic began. As of December 31, the new COVID-related hospital admissions rate had hit a new high of 0.74 per 100,000 children. The high rise in hospital admissions due to COVID-19 fuelled the market growth during the pandemic.
Furthermore, the rise in hospitals is further expected to fuel the market growth. For instance, according to the Organisation for Economic Co-operation and Development updated in May 2022, the number of hospitals in Colombia in 2019 was 10,635 and increased to 10,899 in 2020. Such a rise in hospitals will lead to a rise in hospital admissions, driving the market growth over the forecast period.
Therefore, the factors above are expected to drive this segment’s growth over the forecast period.
North America Is Expected To Hold A Major Share And Expected To Show The Same Pace Over The Forecast Period
North America is expected to hold a major share in the market studied, and it is expected to do the same over the forecast period.
According to the American Hospital Association Hospital Statistics 2022, the number of all hospitals in the United States in 2022 was 6,093. Furthermore, according to the same source, total hospital admissions in the United States are 33,356,853. Such a huge number of hospitals and hospital admissions in the United States will drive the market growth due to the rise in the adoption of ethical drugs under the supervision of physicians, driving the market growth.
The rise in launches of ethical pharmaceuticals in the United States is further expected to drive market growth due to the rise in the adoption of such pharmaceuticals. For instance, in January 2021, the United States Food and Drug Administration approved VERQUVO, a soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization.
Furthermore, in September 2021, the United States Food and Drug Administration (FDA) approved premix Norepinephrine Bitartrate in 5% Dextrose Injection developed by Baxter International Inc. in adult patients with severe, acute hypotension, norepinephrine is used to raise blood pressure (low blood pressure). Such launch of ethical drugs will lead to increased adoption of such drugs driving the market growth.
Moreover, according to the study published in the American Journal of Health-System Pharmacy, titled ‘National trends in prescription drug expenditures and projections for 2020’ in May 2020, Overall prescription drug spending is expected to rise from 4.0 percent to 6.0 percent in 2020, with rises of 9.0 percent to 11.0 percent in clinics and 2.0 percent to 4.0 percent in hospitals, respectively. Such a rise in prescription drug expenditure is further expected to propel market growth.
Therefore, the abovementioned factors are expected to drive the market growth in North America over the forecast period.
Ethical Pharmaceuticals Market Competitor Analysis
The Ethical Pharmaceuticals market is moderately competitive as per the analysis, owing to a few companies currently dominating the market. The market is driven majorly due to the rise in product launches for various indications, research collaborations for the development of novel therapeutics, rise in the distribution of prescription drugs, among others. Some major players dominating the market include Sanofi, Amgen Inc, Merck & Co., Inc, GlaxoSmithKline plc, Novartis AG, and Pfizer Inc, among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Chronic Diseases and Increase in Geriatric Population
4.2.2 Rise in Research Activities For the Development of Novel Ethical Medicines
4.3 Market Restraints
4.3.1 Patent Expiry of Current Ethical Pharmaceuticals
4.3.2 Lengthy Approval Process
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Drug Class
5.1.1 Lipid Regulators
5.1.2 ACE Inhibitors
5.1.3 Respiratory Agents
5.1.4 Narcotic Analgesics
5.1.5 Diuretics
5.1.6 Calcium Antagonists
5.1.7 Hormonal Contraceptives
5.1.8 Others
5.2 By Application
5.2.1 Hospitals and Clinics
5.2.2 Others (Pharmaceutical Company, Contract Drug Manufacturing Organization)
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amgen Inc
6.1.2 AbbVie Inc
6.1.3 Johnson & Johnson
6.1.4 Eli Lilly and Company
6.1.5 Merck & Co., Inc
6.1.6 GlaxoSmithKline plc
6.1.7 Sanofi
6.1.8 Novartis AG
6.1.9 Abbott Laboratories
6.1.10 Otsuka Holdings
6.1.11 F. Hoffmann-La Roche Ltd
6.1.12 Teva Pharmaceutical Industries Ltd.
6.1.13 Pfizer Inc
6.1.14 Takeda Pharmaceutical Company
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
